fda compounding semaglutide enforcement 2025 news New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA warns consumers not to

Such modulation of cAMP is not merely a binary on-off switch but rather a nuanced, dosage-dependent response that fine-tunes neuronal output

Beyond-use date (BUD)

During stress or sympathetic activation, HF tends to drop, while LF may remain steady or rise modestly, shifting the balance toward lower HRV and increased physiological arousal

Connect with a weight loss healthcare provider through Klinic to receive a prescription

Table of adverse effects at pivotal doses The dysesthesia signal of retatrutide: a serious point This is a new finding that no comparative study conducted before 2026 had included

This evolution reflects a growing understanding of the gut-brain-liver axis and the complex neuroendocrine regulation of energy balance